Method for treating hypermenorrhea with uterine therapeutic system

Claim 1

A method for treating hypermenorrhea in a warm blooded animal which method comprises administering to the uterus of the animal from a means sized, shaped and adapted for placement in the uterus a therapeutically effective amount of a progestational steroid for a prolonged period of time to impart relief from said hypermenorrhea.

Claim 2

A method for treating hypermenorrhea in a warm blooded animal which method comprises administering to the uterus of the animal from a means sized, shaped and adapted for placement in the uterus a therapeutically effective amount of a progestational steroid for a prolonged period of time to impart relief from said hypermenorrhea.

Claim 9

A method for the management of hypermenorrhea which comprises administering to the uterus of a warm blooded animal having hypermenorrhea a therapeutically effective amount of a progestational hormone having the following formula: ##STR7## wherein R 1 , R 2 and R 3 are independently selected from the group consisting of hydrogen and lower alkyl; R 4 is a member selected from the group consisting of hydroxyl and acyl; R 5 and R 6 are independently selected from the group consisting of hydrogen, hydroxyl and acyloxy; R 5 and R 6 when taken together consists of a ##STR8## group wherein w is a lower alkyl and p is a member selected from the group consisting of alkyl and phenyl, and x is a member selected from the group consisting of H 2 and oxygen.

Claim 10

A method for the management of hypermenorrhea which comprises administering to the uterus of a warm blooded animal having hypermenorrhea a therapeutically effective amount of a progestational hormone having the following formula: ##STR7## wherein R 1 , R 2 and R 3 are independently selected from the group consisting of hydrogen and lower alkyl; R 4 is a member selected from the group consisting of hydroxyl and acyl; R 5 and R 6 are independently selected from the group consisting of hydrogen, hydroxyl and acyloxy; R 5 and R 6 when taken together consists of a ##STR8## group wherein w is a lower alkyl and p is a member selected from the group consisting of alkyl and phenyl, and x is a member selected from the group consisting of H 2 and oxygen.

Claim 11

A method for the management of hypermenorrhea which comprises administering to the uterus of a warm blooded animal having hypermenorrhea an effective amount of a progestational hormone having the following formula: ##STR9## wherein x is a member selected from the group consisting of oxygen and H 2 ; R 1 is a member selected from the group consisting of lower alkyl and halogen; R 2 is a member selected from the group consisting of lower alkyl and acyloxy; and R 3 is an acyl group wherein the hormone when administered to the uterus alleviates hypermenorrhea.

Claim 12

A method for the management of hypermenorrhea which comprises administering to the uterus of a warm blooded animal having hypermenorrhea an effective amount of a progestational hormone having the following formula: ##STR9## wherein x is a member selected from the group consisting of oxygen and H 2 ; R 1 is a member selected from the group consisting of lower alkyl and halogen; R 2 is a member selected from the group consisting of lower alkyl and acyloxy; and R 3 is an acyl group wherein the hormone when administered to the uterus alleviates hypermenorrhea.

Claim 13

A method for alleviating hypermenorrhea comprising administering to the uterus of a warm blooded animal exhibiting hypermenorrhea a therapeutically effective amount of a progestational steroid having the following formula: ##STR10## wherein R 1 is a member selected from the group consisting of hydroxyl and acyloxy; R 2 is a member selected from the group consisting of hydrogen and acyloxy; and R 3 is a lower alkynyl, and wherein the hormone when administered to the uterus alleviates hypermenorrhea.

Claim 14

A method for alleviating hypermenorrhea comprising administering to the uterus of a warm blooded animal exhibiting hypermenorrhea a therapeutically effective amount of a progestational steroid having the following formula: ##STR10## wherein R 1 is a member selected from the group consisting of hydroxyl and acyloxy; R 2 is a member selected from the group consisting of hydrogen and acyloxy; and R 3 is a lower alkynyl, and wherein the hormone when administered to the uterus alleviates hypermenorrhea.

Claim 15

A method for alleviating hypermenorrhea comprising administering to a warm blooded animal's uterus a progestational steroid of the following formula: ##STR11## wherein R 1 is a member selected from the group consisting of hydrogen and lower alkyl; R 2 is a member selected from the group consisting of acyl and acyloxy; and R 3 is a member selected from the group consisting of hydroxyl and lower alkynyl, and wherein the steroid is administered in a therapeutically effective amount for alleviating hypermenorrhea in an animal suffering with same.

Claim 16

A method for alleviating hypermenorrhea comprising administering to a warm blooded animal's uterus a progestational steroid of the following formula: ##STR11## wherein R 1 is a member selected from the group consisting of hydrogen and lower alkyl; R 2 is a member selected from the group consisting of acyl and acyloxy; and R 3 is a member selected from the group consisting of hydroxyl and lower alkynyl, and wherein the steroid is administered in a therapeutically effective amount for alleviating hypermenorrhea in an animal suffering with same.

Claim 17

A method for treating hypermenorrhea comprising administering to a woman having hypermenorrhea a progestational steroid selected from the group consisting of Δ 4 -pregnene-3-20-dione; 6α-methyl-4-pregnen-17α-ol-3,20-dione; 6α-methyl-17α-acetoxyprogesterone; 17α-ethynyl-17β-hydroxy-4-androsten-3-one; 6α-methyl-17-(1-propynyl)-testerone; 17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one; 19-nor-17-ethynyl-testosterone acetate; dl-13β-ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one; 17-hydroxy-19-nor-17α-pregn-5(10)-en-20-yn-3-one; 19-nor-17α-pregn-4-en-20-yne-3β-17-diol; 17α-ethynyl-4-estrene-3β-17β-diol diacetate; 3-(cyclopentyloxy)-19-nor-17α-pregna-3,5-dien-20-yn-17-ol acetate; 17α-ethynylester-4-en-17β-ol; 17α-acetoxyprogesterone; 17-hydroxypregn-4-ene-3,20-dione; 17α-hydroxypregn-4-ene-3,20-dione hexanoate; 17-hydroxypregesterone 3-cyclopentyl enol ether; 17α-acetoxyprogesterone 3-cyclopentyl enol ether; 17α-hydroxy-6-methyl-pregna-4,6-diene-3,20-dione acetate; 6-chloro-17-hydroxypregna-4,6-diene-3,20-dione acetate; 6,17-dimethyl-pregna-4,6-3,20-dione; 10α-pregna-4,6-diene-3,20-dione; 6-methyl-16-methylene-6-dehydro-17.alpha.-acetoxy-progesterone; R-16α,17-dihydroxy-pregn-4-ene-3,20-dione cyclic 16,17-acetal β-methyl-α-phenyl; 6,16α-dimethyl-6-dehydro-17α-acetoxy-progesterone: 3-(cyclopentyloxy)-pregna-3,5-dien-20; 16α,17-dihydroxypregn-4-ene-3,20-dione; 17α-ethynyl-5-estren-17β-ol; 17α-ol; 17α-ethynyl-17-hydroxy-estra-4,9,11-trien-3-one; 17α-vinyl estr-5(10)-17β-ol-3-one; dl-13β-ethyl-17α-ethynyl-hydroxy-gon-4-en-3-one; and 19-nor-3-desoxy-17-allyltestosterone, and wherein the progestational steroid is administered to the uterus of said woman from an intrauterine therapeutic system in the form of an intrauterine device in a controlled and continuous therapeutic amount sufficient for relieving hypermenorrhea.

Claim 18

A method for treating hypermenorrhea comprising administering to a woman having hypermenorrhea a progestational steroid selected from the group consisting of Δ 4 -pregnene-3-20-dione; 6α-methyl-4-pregnen-17α-ol-3,20-dione; 6α-methyl-17α-acetoxyprogesterone; 17α-ethynyl-17β-hydroxy-4-androsten-3-one; 6α-methyl-17-(1-propynyl)-testerone; 17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one; 19-nor-17-ethynyl-testosterone acetate; dl-13β-ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one; 17-hydroxy-19-nor-17α-pregn-5(10)-en-20-yn-3-one; 19-nor-17α-pregn-4-en-20-yne-3β-17-diol; 17α-ethynyl-4-estrene-3β-17β-diol diacetate; 3-(cyclopentyloxy)-19-nor-17α-pregna-3,5-dien-20-yn-17-ol acetate; 17α-ethynylester-4-en-17β-ol; 17α-acetoxyprogesterone; 17-hydroxypregn-4-ene-3,20-dione; 17α-hydroxypregn-4-ene-3,20-dione hexanoate; 17-hydroxypregesterone 3-cyclopentyl enol ether; 17α-acetoxyprogesterone 3-cyclopentyl enol ether; 17α-hydroxy-6-methyl-pregna-4,6-diene-3,20-dione acetate; 6-chloro-17-hydroxypregna-4,6-diene-3,20-dione acetate; 6,17-dimethyl-pregna-4,6-3,20-dione; 10α-pregna-4,6-diene-3,20-dione; 6-methyl-16-methylene-6-dehydro-17.alpha.-acetoxy-progesterone; R-16α,17-dihydroxy-pregn-4-ene-3,20-dione cyclic 16,17-acetal β-methyl-α-phenyl; 6,16α-dimethyl-6-dehydro-17α-acetoxy-progesterone: 3-(cyclopentyloxy)-pregna-3,5-dien-20; 16α,17-dihydroxypregn-4-ene-3,20-dione; 17α-ethynyl-5-estren-17β-ol; 17α-ol; 17α-ethynyl-17-hydroxy-estra-4,9,11-trien-3-one; 17α-vinyl estr-5(10)-17β-ol-3-one; dl-13β-ethyl-17α-ethynyl-hydroxy-gon-4-en-3-one; and 19-nor-3-desoxy-17-allyltestosterone, and wherein the progestational steroid is administered to the uterus of said woman from an intrauterine therapeutic system in the form of an intrauterine device in a controlled and continuous therapeutic amount sufficient for relieving hypermenorrhea.

Claim 22

A method for treating hypermenorrhea which method comprises administering from an intrauterine device sized, shaped and adapted for placement in the uterus and formed of a biologically inert polymer containing 0.1 milligrams to 5 grams of progestational steroid, from 5 nanograms to 100 micrograms of the progestational steroid per day over a prolonged period of time to the uterus of a woman having hypermenorrhea to impart relief from same.

Claim 23

A method for treating hypermenorrhea which method comprises administering from an intrauterine device sized, shaped and adapted for placement in the uterus and formed of a biologically inert polymer containing 0.1 milligrams to 5 grams of progestational steroid, from 5 nanograms to 100 micrograms of the progestational steroid per day over a prolonged period of time to the uterus of a woman having hypermenorrhea to impart relief from same.

Claim 24

A method for treating hypermenorrhea which method comprises (a) placing an intrauterine device sized, shaped and adapted for placement and retention in the uterus and formed with an internal reservoir containing from 0.1 milligrams to 5 grams of a progestational steroid and (b) administering from the device from 5 nanograms to 100 micrograms of the progestational steroid per day over a prolonged period of time to the uterus of a woman having hypermenorrhea to impart relief from same.

Claim 25

A method for treating hypermenorrhea which method comprises (a) placing an intrauterine device sized, shaped and adapted for placement and retention in the uterus and formed with an internal reservoir containing from 0.1 milligrams to 5 grams of a progestational steroid and (b) administering from the device from 5 nanograms to 100 micrograms of the progestational steroid per day over a prolonged period of time to the uterus of a woman having hypermenorrhea to impart relief from same.